Search Result for "Prostate Cancer"
Cancer Treatment
Pluvicto

UT Health San Antonio offers a revolutionary therapy for prostate cancer called Pluvicto®. We are one of the only centers in South Texas to offer this innovative treatment, providing new hope for advanced prostate cancer patients.

Cancer Treatment
Robotic Prostatectomy Surgery

If you have prostate cancer, your doctor may recommend surgery to remove the prostate gland. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, you’re in the hands of leading prostate cancer experts. Our team includes surgeons with fellowship training focused on prostate cancer surgery. We have specialized expertise in removing cancer using robotics technology (called a robotic prostatectomy). This precise technique helps us treat cancer with less impact on your life.

Cancer Treatment
Stereotactic Body Radiotherapy (SBRT)

At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our radiation oncologists combine advanced technologies with exceptional cancer expertise.

Clinical Trial

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

This is a Phase 1a, first-in-human, open-label dose-escalation study to determine the RDR and/or MTD, and to assess the DLT of INV-9956. The safety, tolerability, PK/PD, and preliminary antitumor activity of INV-9956 will be assessed in adult patients with advanced mCRPC.

Cancer Treatment
Brachytherapy

Brachytherapy, also called internal radiation therapy, can effectively treat certain cancers, such as cervical and prostate cancers, in novel ways. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, you receive care from skilled experts who are leaders in their field. Our experienced radiation oncologists perform intricate brachytherapy procedures with your safety and comfort in mind at all times.

Clinical Trial

An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In

The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.